Majority-owned Nevada company to expand 8-inch and 12-inch wafer sorter and AOI output for global market projected to reach $9.7 billion by 2030

Subject to finalization of definitive agreements, TechForce Advanced Manufacturing’s operation is expected to begin production and contribute initial revenue to the Company during Q4 2026, corresponding with the Company’s fiscal second quarter

LOS ANGELES, Sept. 17, 2026 (GLOBE NEWSWIRE) — via IBN — Nightfood Holdings, Inc. (OTCQB: NGTF) (“Nightfood” or the “Company”), doing business as TechForce Robotics, today announced the formation of TechForce Advanced Manufacturing, Inc. (“TechForce Advanced Manufacturing”), a Nevada corporation established to pursue a strategic advanced-manufacturing partnership with JUN LONG MACHINE INDUSTRIAL CO., LTD. (“JUN LONG”). The establishment of TechForce Advanced Manufacturing marks a key initial step in the Company’s planned commercial expansion into the semiconductor manufacturing equipment industry.

TechForce Advanced Manufacturing is intended to be owned 51% by Nightfood and 49% by JUN LONG. Nightfood will provide strategic oversight, commercialization support, public-company infrastructure and access to capital-raising resources. JUN LONG will contribute technical know-how, manufacturing expertise, product-development capabilities and customer relationships.

Calendar Q4 2026 Production and Revenue Target
Both parties anticipate finalizing and signing the definitive agreement within the next several weeks. TechForce Advanced Manufacturing is preparing additional manufacturing capacity, suppliers, engineering support and customer-integration resources to address near-term demand.

JUN LONG currently holds purchase orders from key customers, representing existing demand that TechForce Advanced Manufacturing expects to begin fulfilling upon completion of the definitive agreement. This order backlog supports the Company’s target of commencing production and generating initial revenue in calendar Q4 2026, subject to completion of the definitive agreement, customer orders and applicable qualification requirements. The timing and amount of revenue will depend on production schedules, delivery, customer acceptance and applicable U.S. GAAP requirements.

Expanding Wafer Sorter and AOI Production
The partnership’s immediate commercial focus is expanding production of an automated Wafer Sorter and Automated Optical Inspection (“AOI”) system designed for both 8-inch and 12-inch silicon wafers. The system combines robotic wafer handling, automated inspection and grading, identification-based sorting, front-side optical character recognition (“OCR”) and optional Semiconductor Equipment Communication Standard (“SECS”) factory connectivity.

The system supports inspection, identification, transfer and sorting within semiconductor and Chip-on-Wafer-on-Substrate (“CoWoS”) related advanced-packaging production. CoWoS enables processors, chiplets and high-bandwidth memory to be integrated into high-performance packages used in artificial intelligence and advanced computing systems.

According to an independent industry report, the global semiconductor wafer inspection equipment market is projected to grow from approximately $7.05 billion in 2026 to approximately $9.67 billion by 2030.

About Nightfood Holdings, Inc. (d/b/a TechForce Robotics)
Nightfood Holdings, Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The Company integrates robotics, artificial intelligence and software-driven systems to optimize operations, improve efficiency and enable next-generation automation.

TechForce Robotics partners with organizations to design and deploy customized robotic solutions that address evolving operational requirements.

Learn more: www.techforcerobotics.com

About TechForce Advanced Manufacturing
TechForce Advanced Manufacturing, Inc. is a Nevada corporation formed to develop, manufacture, commercialize, install and support semiconductor automation and inspection systems. Its initial focus is expanding Wafer Sorter and AOI production for wafer-based semiconductor and CoWoS-related advanced-packaging applications, while pursuing future applications supporting emerging Chip-on-Panel-on-Substrate (“CoPoS”) manufacturing processes.

Forward-Looking Statements
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” “plan,” “project,” “target,” “will” and similar expressions identify forward-looking statements.

These statements include, among other things, expectations concerning the completion and timing of definitive agreements; the proposed ownership and operating structure of TechForce Advanced Manufacturing; the expansion of manufacturing capacity; customer demand and orders; the commencement of production; the timing and amount of revenue recognition; and the development of additional semiconductor automation and advanced-packaging applications.

Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements. Such statements are based on the Company’s current expectations and are subject to risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. Investors are encouraged to review the Company’s filings with the Securities and Exchange Commission for additional information regarding applicable risks and uncertainties.

Investor Relations, Media Relations and Corporate Communications
Investor Relations
ir@nightfoodholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements

MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow® system, with 31 consoles sold year-to-date in 2026. The Company’s year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026.

“Selling 31 consoles at this point in the year is an important indicator of the commercial progress we are making to expand our installed base of Aquadex systems,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “We are particularly encouraged by our year-to-date performance in that it is being driven by hospitals that recognize the level of patient care associated with Aquadex. This shows that they are making the informed, deliberate decision to incorporate Aquadex into their fluid-management programs.”

Each additional Aquadex console expands the Company’s installed base and creates opportunities for recurring utilization of the Company’s single-use blood circuits. The Aquadex SmartFlow system consists of a console, catheter, and disposable blood circuit set used to provide controlled ultrafiltration therapy. As the installed base expands and utilization increases, Nuwellis believes console placements can support continued growth in recurring consumable revenue.

Notably, the Company’s highest historical console-placement years included the COVID-19 period, when hospitals expanded access to fluid-removal technologies in response to extraordinary critical-care demand. Nuwellis’ 2026 performance is being achieved in a normalized hospital environment and reflects continued adoption of Aquadex in the U.S. across the Company’s core pediatric, critical-care, and heart-failure markets.

The 2026 console momentum builds upon Nuwellis’ broader commercial performance. During the first half of 2026, the Company reported U.S. revenue growth of 26% compared with the prior-year period, with growth across pediatrics, critical care, and heart failure. The Company believes the combination of an expanding installed base, increasing consumable utilization, and continued commercial execution positions the Company to build a larger and more durable recurring-revenue business.

McCormick continued, “Our objective is to build productive Aquadex programs where clinicians use the technology to treat patients effectively when diuretics fail. Expanding the installed base creates the foundation for increasing utilization, recurring circuit revenue and broader adoption of Aquadex therapy.”

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

MARKHAM, Ontario, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company“) (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Stonemont On the Park (“Stonemont”), a 305-suite retirement residence in Ottawa, Ontario.

The property opened in 2024 and is approximately 99% occupied. Stonemont is conveniently located in Ottawa’s east end and offers high-quality amenities as well as above- and below-grade parking.

The gross purchase price for Stonemont is approximately $170.7 million, or $560,000 per suite. The transaction includes an additional $10.0 million earnout contingent upon exceeding certain financial targets and is expected to close in Q4 2026, subject to regulatory and customary closing conditions. The Company intends to finance the acquisition with available cash on hand and its credit facilities.

“With the addition of Stonemont, we are further expanding Sienna’s retirement platform in a key market,” said Nitin Jain, President and Chief Executive Officer. “Following this transaction, we will have added approximately $1.2 billion of assets through acquisitions and developments since 2025. We continue to build on this momentum with a strong acquisition pipeline and Sienna’s $625 million joint venture partnership with Fiera Infrastructure to accelerate long-term care redevelopments. These opportunities allow us to further scale our platform, enhance the experience of Sienna’s residents and team members, while creating long-term value for our shareholders.”

About Sienna Senior Living

Sienna Senior Living Inc. (TSX: SIA) offers a full range of seniors’ living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,500 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.

Forward-Looking Statements

Certain of the statements contained in this news release are forward-looking statements and are provided for the purpose of presenting information about management’s current expectations and plans relating to the future. Readers are cautioned that such statements may not be appropriate for other purposes. These statements generally use forward-looking words, such as “anticipate,” “continue,” “could,” “expect,” “may,” “will,” “estimate,” “believe,” “goals”, “target” or other similar words and are based on the Company’s expectations, estimates, forecasts and projections. These statements are subject to significant known and unknown risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such statements and, accordingly, should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. The forward-looking statements in this news release are based on information currently available and what management currently believes are reasonable assumptions. The Company does not undertake any obligation to publicly update or revise any forward-looking statements except as may be required by applicable law.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Hung
Chief Financial Officer and Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca

Nancy Webb
Executive Vice President, Corporate Affairs and Marketing
(905) 477-4006 ext. 3030
nancy.webb@siennaliving.ca

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) — Pure Cycle Corporation (Nasdaq Capital Market: PCYO) (“Pure Cycle”, “we”, “us” or “our”) announced today that Mark W. Harding, President and Chief Executive Officer, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

“We are pleased to participate in the Lytham Partners Fall 2026 Investor Conference,” commented Mr. Harding. “The virtual format allows us to reach a broad audience of institutional and individual investors and to detail our value proposition combining water and land development here in Colorado. Pure Cycle continues to drive shareholder value with development of our master planned community, Sky Ranch, while expanding Rangeview’s municipal water and wastewater system that serves Sky Ranch and other customers throughout our service area.”

Company Webcast

Pure Cycle’s webcast presentation can be viewed beginning at 1:45 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed at https://app.webinar.net/Xk3b9WmM5gE or by visiting the conference website at https://lythampartners.com/fall2026/. A replay will be available following the event.

1×1 Meetings

Management will participate in virtual one-on-one meetings with investors throughout the conference. To arrange a meeting, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

Company Information

Pure Cycle continues to strengthen its operations, build its balance sheet, and drive recurring revenues. We operate in three distinct business segments, each of which complements the others. At our core, we are a vertically integrated wholesale water and wastewater service provider. In 2017, we launched our land development segment, which develops master planned communities on land we own and to which we provide water and wastewater services. In 2021, we launched our newest line of business, the rental of single-family homes located at Sky Ranch, which provides long-term recurring revenues, furthers our land development operations, and adds more customers to our water resource segment.

Additional information, including our recent press releases and SEC filings, is available at www.purecyclewater.com, or you may contact our President, Mark W. Harding, or our CFO, Marc Spezialy, at 303-292-3456 or info@purecyclewater.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are all statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect or anticipate will or may occur in the future, such as statements about the following: our participation in the Lytham Partners Fall 2026 Investor Conference; our development activities at Sky Ranch; and the continued expansion of our regional water and wastewater system. The words “anticipate,” “likely,” “may,” “should,” “could,” “will,” “believe,” “estimate,” “expect,” “plan,” “intend,” “potential” and similar expressions are intended to identify forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ from projected results include, without limitation: home mortgage interest rates, inflation, trade policies, tariffs, and other factors impacting the housing market and home sales; the risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended August 31, 2025; and those factors discussed from time to time in our press releases, public statements and documents filed or furnished with the U.S. Securities and Exchange Commission.

SOURCE: Pure Cycle Corporation

Industry Veterans Appointed in New York and Boston, Augmenting Venture Banking and Venture Capital Coverage Nationwide

ST. LOUIS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced the addition of three senior leaders to its Venture Banking business, further solidifying its presence across the East Coast venture ecosystem.

Chris Morrison, Matt Scott, and Arianne Perry, each of whom previously held senior roles at Silicon Valley Bank (“SVB”), join Stifel to expand Venture Banking and Venture Capital Coverage efforts in Boston and New York. Their appointments strengthen the firm’s ability to serve the banking and financing needs of venture capital-backed technology companies, their founders, and investors.

Chris Morrison joins as a Managing Director, focused on Venture Banking in the Boston market. Matt Scott joins as a Managing Director, focused on Venture Banking in the New York City market. Arianne Perry joins as a Managing Director, Venture Capital Coverage, focused on expanding the firm’s investor coverage presence in New York City and the East Coast.

“We are pleased to welcome Chris, Matt, and Arianne to Stifel as we continue to build our Venture Banking business,” said Stifel Chairman and CEO Ron Kruszewski. “The innovation economy is an important growth opportunity for Stifel. Their experience and relationships strengthen our ability to serve entrepreneurs and investors with the full capabilities of Stifel, from early stage financing through the public markets and beyond.”

Prior to joining Stifel, Chris Morrison spent 15 years at SVB, including three years leading the growth stage practice and more than a decade in credit and venture lending at the bank.

Most recently, Matt Scott worked at TriplePoint Capital, where he focused on private credit investments in leading high-growth technology companies. Before this, he led SVB’s Enterprise Software team in New York City, served as a venture capital investor at Basecamp Fund, and served as a founder and operator at multiple venture capital-backed tech companies.

Arianne Perry previously led SVB’s East Coast Investor Coverage from New York City, providing venture capital investors with tailored financial services and supporting venture-backed technology companies with capital, credit, and banking solutions. She also spent nearly 10 years as a start-up founder and lead operator in the New York City venture ecosystem. Prior to that, she worked in various finance and investing roles at JPMorgan and Google.

“Stifel has built a differentiated Venture Banking platform that combines a deep understanding of the venture capital ecosystem with the capabilities of a broader financial services firm,” said Morrison, Scott, and Perry in a joint statement. “We look forward to partnering with founders and investors from the earliest stages of a company’s growth through pre-IPO and beyond, providing the banking, financing, and advisory solutions they need as their businesses evolve.”

The hires build on Stifel’s continued investment in its Venture Banking practice, including the recent addition of dedicated Project Finance and Life Sciences and Healthcare teams. The business now includes more than 125 client-facing professionals located in every major U.S. tech market.

Stifel’s Venture Banking practice serves more than 500 leading, high-growth companies across a diverse range of industries including artificial intelligence, climate technology, consumer technology, cybersecurity, fintech, healthcare, and more. To date, the platform has supported their innovation with more than $12 billion in loan commitments.

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement.

Stifel Bank and Stifel Bank & Trust, Members FDIC, offer a full range of consumer and commercial lending solutions, including Venture Banking and Venture Capital Coverage. To learn more about Stifel, please visit the Company’s website at Stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases. 

Media Contacts

Neil Shapiro, +1 (212) 271-3447
shapiron@stifel.com

Evan Roesen, +1 (212) 271-3610
roesene@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610
investorrelations@stifel.com

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates.

1. Change of Auditor:

The Company determined that it was in its future best interest to pursue engaging an auditor who is capable of conducting a U.S. Public Company Accounting Oversight Board (“PCAOB”) mandate. The mandate was offered to Clearhouse LLP (the “Predecessor Auditor”), which advised the Company that it was unable to accept the engagement.

Following a request for proposals from multiple audit firms, the Company decided to replace the Predecessor Auditor with Davidson & Company LLP (the “Successor Auditor”).

On September 14, 2026, the Board of Directors of the Company passed a resolution to appoint Davidson & Company LLP and accepted the resignation of the Predecessor Auditor.

The Company extends its gratitude to Clearhouse LLP for its past service and looks forward to working with Davidson & Company LLP.

2. Water Tower Research

On April 23, 2026, PharmAla entered into a Subscription Services Agreement (the “Agreement”) with Water Tower Research LLC (“WTR”), a wholly owned subsidiary of alphaDIRECT Group LLC.

Under the Agreement, WTR will provide PharmAla with company research, investor engagement and stakeholder communication and intelligence programs through the production of research reports and supporting content (collectively referred to as “WTR Content”) distributed through WTR’s proprietary digital delivery infrastructure.

PharmAla agreed to pay $58,000 (“Annual Fee”) for access to the Subscription Services, which commenced on May 15, 2026 (“Effective Date”), upon execution of this Agreement. This Agreement has a one (1) year term (the “Term”) ending on May 15, 2027. There is no equity linked compensation for WTR under the terms of the Agreement.

In connection with the Subscription Services, PharmAla will receive:

  • Ongoing analyst support and coverage of Clients company which may include but is not limited to: Initiation of Coverage (“IOC”) Fireside Chats – Video Update Notes
  • Management Series Reports
  • Quarterly Earnings Notes
  • WTR’s Small-Cap Spotlight Podcast
  • Industry Notes Inclusion
  • Expert Series – Video
  • WTR Symposium Series Events
  • Symposium Series Recap Notes  

WTR shares content through their digital delivery infrastructure, which includes their own website, social media and with direct mailing lists.

3. Oak Hill Financial Inc.

On April 21, 2026, PharmAla signed a contract with Oak Hill Financial Inc. (“Oak Hill”). Oak Hill will provide business and capital markets advisory services, including raising the Company’s profile with the investment community, and assisting dissemination of investor presentation materials.

The initial term of the agreement was two months. Following the initial term, the agreement may be extended on a month-to-month basis at the sole discretion of the Company. Upon renewal, the monthly fee will remain the same. Either party may terminate the agreement after the initial term upon five (5) business days’ written notice. The Company will pay Oak Hill a monthly advisory fee of $12,000 plus pre-approved out-of-pocket expenses.

There are no performance factors under the agreement with Oak Hill, and Oak Hill will not receive any common shares or other securities of the Company as compensation. Oak Hill has no present interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest. Oak Hill is an arm’s length party to the Company.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –

– PDUFA Target Action Date of November 22, 2026 –

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company’s lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan. The presentations will report skeletal muscle and cardiac outcomes through 24 months, building on the previously reported 12-month HOPE-3 results. Of the 106 patients randomized in HOPE-3, 82 reached the 24-month time point, comprising 40 originally assigned to Deramiocel and 42 to placebo.

“These HOPE-3 24-month data, along with additional analyses supporting Deramiocel’s potential safety and efficacy, were part of our recent major amendment to the Deramiocel BLA,” said Linda Marbán, Ph.D., CEO of Capricor. “We look forward to presenting these results at the World Muscle Society Congress.”

Beyond the Deramiocel program, Capricor will also present two preclinical posters from its StealthX™ exosome platform.

WMS Presentations

Title: Deramiocel slows upper limb decline in the HOPE-3 OLE: cross-phase delayed-start analysis and 2-year comparison with natural history
Presenting author: Dr. Craig McDonald, University of California, Davis
Details: Late-breaking poster session

Title: HOPE-3, a phase 3 study of deramiocel, an allogeneic cell therapy, in advanced Duchenne muscular dystrophy: evidence to support both musculoskeletal and cardiac efficacy
Presenting author: Dr. Craig McDonald
Details: Oral presentation, clinical trial updates session, October 3, 2026

Title: Engineered muscle-targeting extracellular vesicles for systemic delivery of micro-dystrophin: novel redosable strategy for Duchenne muscular dystrophy
Presenting author: Mafalda Cacciottolo, Ph.D., Capricor Therapeutics
Details: Poster session 2, DMD treatments, September 30, 2026

Title: Delivery of acid α-glucosidase by muscle-targeting extracellular vesicles: a new road for Pompe disease treatment
Presenting author: Mafalda Cacciottolo, Ph.D.
Details: Poster session 3, Glycogenoses, October 2, 2026

Copies of the presentations and posters will be added to the publications section of the Capricor website following each presentation. The full WMS 2026 program is available at https://www.wms2026.com/page/programme.

About the HOPE-3 Study

HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Deramiocel in patients with Duchenne muscular dystrophy. The study enrolled 106 patients, randomized to receive Deramiocel or placebo administered intravenously every three months over a 12-month treatment period. HOPE-3 met its primary endpoint, with Deramiocel slowing decline in upper limb function by 54 percent versus placebo as measured by Performance of the Upper Limb (PUL) version 2.0 (p=0.03). One-year results were published in The Lancet in July 2026. Patients who completed the randomized portion of the study were eligible to continue receiving Deramiocel in an open-label extension.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.

About Deramiocel

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease designation may qualify Capricor for a Priority Review Voucher upon approval.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Agreement Reserves Approximately $53 Million of Pendergrass Manufacturing Capacity for Northern Ontario Edge AI Data Center Projects

Represents First Commercial Capacity Reservation Under Previously Announced Approximately $200 Million Utility-Scale Framework

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced that its majority-owned subsidiary, NeoVolta Power, LLC (“NeoVolta Power”), has entered into a binding capacity reservation agreement with Infinite Grid Capital (“IGC”) to provide battery energy storage system (“BESS”) equipment for North Ontario Edge artificial intelligence datacenter (“Edge AIDC”) projects for calendar year 2027.

Today’s announcement represents the first major commercial commitment under NeoVolta Power’s previously announced utility-scale framework with IGC, which contemplates approximately 1.1 GWh of potential BESS deployments and approximately $200 million of potential supply across multiple markets. The approximately $53M binding commitment advances the Company’s strategy of converting early utility-scale demand visibility into binding commercial relationships as its Pendergrass manufacturing platform progresses through commissioning and production-ramp activities.

“This is an important commercial milestone for NeoVolta Power and a meaningful validation of the platform we have built at Pendergrass,” said Ardes Johnson, Chief Executive Officer of NeoVolta. “The project demonstrates how our BESS manufacturing, a differentiated supply-chain strategy, and scalable energy-storage products can address the rapidly growing power-infrastructure needs of data centers and other energy-intensive customers. As we advance the production ramp at Pendergrass, our focus is on executing this initial commitment and converting additional qualified demand into binding customer orders.”

Utility-Scale Demand Validation

The capacity reservation agreement is intended to support the Northern Ontario Edge AIDC project and represents an initial commercial step within NeoVolta’s broader relationship with IGC. The relationship was previously announced as a non-binding framework spanning approximately 1.1 GWh of potential demand.

The Company believes the initial data-center-related commitment is strategically significant. Growth in artificial intelligence and data-center infrastructure is increasing the need for reliable, scalable power solutions, and BESS is expected to play an increasingly important role in supporting grid reliability, load management, and project-level energy resilience. The commitment provides commercial validation for NeoVolta Power’s utility-scale product offering and its domestic BESS manufacturing strategy.

Pendergrass Grand Opening

NeoVolta will host a grand-opening ceremony for its NeoVolta Power facility in Pendergrass, Georgia, later today. Members of NeoVolta management, key strategic partners, media, and local officials are expected to attend.

The event marks the official opening of the Company’s 210,600-square-foot facility, a purpose-built domestic BESS manufacturing platform designed to assemble commercial, industrial, and utility-scale energy-storage products. The Company’s initial Pendergrass production line is advancing through commissioning and Site Acceptance Testing, and the production ramp remains on track for the fourth quarter of calendar 2026.

NeoVolta expects to provide additional updates regarding the commissioning process, manufacturing milestones, and commercial activity as appropriate.

About Infinite Grid Capital

Infinite Grid Capital (“IGC”) is an energy infrastructure investment platform that develops and finances large-scale power projects, including battery energy storage systems, hybrid energy hubs, and dedicated power solutions for data centers across North America and selected global markets, including key U.S. power regions such as California, Texas, and the Southeastern United States. IGC focuses on building reliable and flexible energy assets that ensure continuous power for AI workloads, industrial operations, and other mission-critical facilities. Infinite Grid Capital is an existing strategic investor in NeoVolta and provides offtake origination and related advisory services in connection with NeoVolta Power’s BESS manufacturing operations.

For more information, visit www.infinitegridcapital.com.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding the Company’s business strategy, plans, objectives, expectations, and future operations; the anticipated timing and benefits of the Company’s manufacturing activities; the Company’s ability to execute its production ramp and achieve manufacturing and commercial milestones; anticipated customer demand, project opportunities, and order conversion; and the Company’s growth plans and future financial and operating performance.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to market conditions; customer demand; the Company’s ability to execute its business strategy and manufacturing plans; supply-chain availability and costs; project development, permitting, construction, and deployment activities; the availability of financing; changes in laws, regulations, tax incentives, tariffs, or trade policies; competition; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

NEOV Investors
Bryan Baritot
Alliance Advisors IR
ir@neovolta.com  

NEOV Media
Email: press@neovolta.com
Phone: 800-364-5464

  • Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome
  • Top-line results remain on track for late November 2026

NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company’s pivotal Phase 3 clinical trial (SGT-610-01) evaluating SGT-610 (patidegib gel, 2%) for the prevention of BCC (basal cell carcinoma) lesions in adult patients with Gorlin syndrome.

The achievement of last patient last visit (LPLV) marks the completion of the patient treatment and follow-up phase of the study. The Company is now proceeding with database lock, followed by statistical analysis of the study results. Sol-Gel expects to report top-line results in late November 2026. The Company, investigators and patients remain blinded to treatment assignment.

The randomized, double-blind, vehicle-controlled Phase 3 study enrolled 113 patients with Gorlin syndrome, of whom 102 completed the study. Patients were randomized to receive SGT-610 or vehicle for 12 months of treatment. The primary endpoint of the study is the number of new BCCs on the face at month 12 after twice daily treatment. Secondary endpoints include the number of new surgically eligible BCCs (SEBCCs).

Mr. Mori Arkin, Executive Chairman and CEO of Sol-Gel, stated: “Reaching last patient last visit represents an important milestone for the SGT-610 program and brings us closer to understanding its potential to address the significant unmet need in patients with Gorlin syndrome. We are grateful to the patients, investigators and clinical site teams whose participation and commitment made this study possible. We look forward to completing the analysis and reporting the results.”

About Sol-Gel Technologies

Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. including, but not limited to statements regarding the timing of the release of top-line results for the Phase 3 program of SGT-610 in Gorlin syndrome. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the risk of a delay in reporting the top-line results of Sol-Gel’s pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, that we will not successfully complete the Gorlin Phase 3 clinical trial or that such clinical trial will fail to meet its primary endpoint or one or more of its secondary endpoints as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators’ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators’ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators’ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the security situation in Israel. These factors and other important factors discussed in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.

Sol-Gel Investor Relations:
Eyal Ben-Or
Chief Financial Officer
ir@sol-gel.com

TOKYO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer, today announced the opening of reservations for JINRYU HOTEL IZUMO, a new luxury Japanese-style all-suite hotel designed for extended stays near Izumo Taisha, one of Japan’s most historic landmarks. Reservations opened on September 1, 2026.

Located at 597-2 Shurimen, Taisha-cho, Izumo-shi, Shimane, the four-story property features six large suites, each accommodating six or more guests. The top-floor living room offers a direct view of Izumo Taisha’s grand torii gate.

“We created JINRYU HOTEL IZUMO to offer guests a quiet, restorative place to stay in one of Japan’s most historic regions. Our focus was on spacious design and a calm environment that supports extended stays.” — Eiji Nagahara, Representative Director, President, and Chief Executive Officer, Lead Real Estate Co., Ltd.

The JINRYU HOTEL series was developed through a collaboration between Lead Real Estate and Ryuka First-Class Architect Office, led respectively by President Eiji Nagahara and architect Hiroshi Fuwa. Each suite provides over 60 square meters of space, with complimentary on-site parking available for guests with advance reservations.

Lead Real Estate Co., Ltd

The exterior of JINRYU HOTEL IZUMO (Source: Lead Real Estate)

Lead Real Estate Co., Ltd

Suite interior at JINRYU HOTEL IZUMO (Source: Lead Real Estate)

About Lead Real Estate Co., Ltd.

Lead Real Estate Co., Ltd is a Japanese developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The Company also operates hotels in Tokyo and leases apartment units in Japan and Dallas, Texas. For more information, visit https://www.lead-real.co.jp/en/.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and other factors that may affect future results, as described in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information

Ken Takahashi
Chief Financial Officer
Lead Real Estate Co., Ltd.
Email: k-takahashi@lead-real.co.jp
Tel: +81 3-5784-5127

AUM Advisors
Crocker Coulson
Email: crocker.coulson@aumadvisors.com
Tel: +1 (646) 652-7185

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/a4134598-9881-41f2-9657-467160da6e99

https://www.globenewswire.com/NewsRoom/AttachmentNg/a2154830-d48e-4f96-8d17-9b6fa9bab33b

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.